Clinical Trials Sponsored by Tioga Pharmaceuticals

Total 19761 results

Ferring Pharmaceuticals

Completed

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Septic Shock

Denmark, United States, Belgium, Canada
Anthera Pharmaceuticals

Completed

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

IgA Nephropathy

Czechia, Germany, Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand, United Kingdom
Inovio Pharmaceuticals

Completed

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

Healthy

United States
Ferring Pharmaceuticals

Completed

Study of the Cleavage of the Egg in Relation to the Stimulation Treatment

Female Infertility

Denmark
Jazz Pharmaceuticals

Approved for marketing

EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML (401)

Secondary AML

United States
Deltanoid Pharmaceuticals

Completed

A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
Sunesis Pharmaceuticals

Completed

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

Epithelial Ovarian Cancer

United States, Canada
Regeneron Pharmaceuticals

Terminated

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (UPSURGE)

Gout

United States
Braeburn Pharmaceuticals

Completed

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

Schizophrenia

United States
Alexion Pharmaceuticals

Terminated

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Antiphospholipid (aPL)-Positive

United States, Italy, Brazil, France, Japan, United Kingdom
Ferring Pharmaceuticals

Completed

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary (IMPACT)

Nocturia

United States
Ferring Pharmaceuticals

Completed

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Prostate Cancer

Finland, France, Germany
Avanir Pharmaceuticals

Terminated

Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

Pseudobulbar Affect (Involuntary Laughing and/or Crying)

United States
Ferring Pharmaceuticals

Completed

Effect of Oxytocin Antagonist on Reduction of Uterine Contractions (EFFORT)

In Vitro Fertilisation (IVF) Treatment

Czechia, Belgium, Spain
Ferring Pharmaceuticals

Completed

Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old. (SHOview)

Ovarian Hyperstimulation Syndrome (OHSS)

France
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) (Taski-3)

Rheumatoid Arthritis

Belgium, United States, Colombia, France, Germany, Italy, Peru
Regeneron Pharmaceuticals

Completed

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 (PRE-SURGE1)

Intercritical Gout

United States, Canada
Regeneron Pharmaceuticals

Completed

PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

Gout

Germany, Taiwan, India, South Africa, Indonesia
KAI Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
Avanir Pharmaceuticals

Completed

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura (COMPASS)

Migraine | Headaches

United States
KAI Pharmaceuticals

Completed

Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

Secondary Hyperparathyroidism
Concert Pharmaceuticals

Completed

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

Healthy

United States
Ferring Pharmaceuticals

Completed

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Septic Shock

Denmark, Belgium
Prolong Pharmaceuticals

Completed

SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer (LU)

Leg Ulcer

Dominican Republic, Panama
Merrimack Pharmaceuticals

Withdrawn

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Colorectal Cancer
Neurotech Pharmaceuticals

Completed

A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Regeneron Pharmaceuticals

Completed

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

Healthy Volunteers

United States
ASLAN Pharmaceuticals

Completed

A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects

Healthy Elderly Subjects (Age ≥55 Years)

Singapore
TetraLogic Pharmaceuticals

Unknown

Safety and Efficacy Study of SHAPE Gel in Alopecia Areata

Alopecia Areata
TetraLogic Pharmaceuticals

Unknown

Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma

Cutaneous T-Cell Lymphoma (CTCL)

United States
TetraLogic Pharmaceuticals

Terminated

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States, Spain, Australia, Germany
Regeneron Pharmaceuticals

Completed

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Healthy

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
SciClone Pharmaceuticals

Unknown

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Non-Small Cell Lung Cancer

Italy
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

T Cell Lymphoma

United States, Canada
Tarix Pharmaceuticals

Completed

Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)

Miscellaneous Peripheral Blood Cell Abnormalities

United States
Tarix Pharmaceuticals

Withdrawn

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Hematologic Malignancies

United States
Tarix Pharmaceuticals

Withdrawn

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Hematologic Malignancies

United States
Jazz Pharmaceuticals

Withdrawn

A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.

Renal Insufficiency | Kidney Disease
Jazz Pharmaceuticals

Terminated

A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis

Head and Neck Squamous Cell Carcinoma

United Kingdom
Merrimack Pharmaceuticals

Completed

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma

United States, France
Peregrine Pharmaceuticals

Withdrawn

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Non-Small Cell Lung Cancer
Alnylam Pharmaceuticals

Completed

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Familial Amyloidotic Cardiomyopathy (FAC)

United States, France, Spain, United Kingdom, Belgium, Brazil
Avanir Pharmaceuticals

Completed

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

Pain | Diabetic Neuropathy

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions (SKINDLE)

Lupus Erythematosus, Systemic | Lupus Erythematosus, Discoid

United States, Canada
Avanir Pharmaceuticals

Completed

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Stroke | Parkinson's Disease | Traumatic Brain Injury | Alzheimer's Disease

United States
Santhera Pharmaceuticals

Completed

A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients (MICONOS)

Friedreich's Ataxia

Netherlands, Austria, United Kingdom, Belgium, France, Germany
Rigel Pharmaceuticals

Completed

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

United States
Threshold Pharmaceuticals

Unknown

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Solid Tumors

United States

3

Subscribe